IBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-30), iBio's share price is $2.47. iBio's Book Value per Share for the quarter that ended in Mar. 2024 was $2.92. Hence, iBio's PB Ratio of today is 0.85.
The historical rank and industry rank for iBio's PB Ratio or its related term are showing as below:
During the past 13 years, iBio's highest PB Ratio was 58.20. The lowest was 0.07. And the median was 3.40.
During the past 12 months, iBio's average Book Value Per Share Growth Rate was -86.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -57.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -34.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -23.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of iBio was 148.10% per year. The lowest was -57.80% per year. And the median was -4.50% per year.
The historical data trend for iBio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iBio Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 5.79 | 5.49 | 3.03 | 0.91 | 0.81 |
iBio Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PB Ratio | Get a 7-Day Free Trial | 1.89 | 0.81 | 0.64 | 0.48 | 1.39 |
For the Biotechnology subindustry, iBio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, iBio's PB Ratio distribution charts can be found below:
* The bar in red indicates where iBio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
iBio's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Mar. 2024) |
= | 2.47 | / | 2.919 | |
= | 0.85 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
iBio (AMEX:IBIO) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of iBio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Martin Brenner | officer: Chief Scientific Officer | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Felipe Duran | officer: Interim CFO | 8800 HSC PARKWAY, BRYAN TX 77807 |
William D Clark | director | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
Evert B. Schimmelpennink | director | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Isett Thomas Francis 3rd | director, officer: CEO and Executive Chairman | C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022 |
Robert Matthew Lutz | officer: See Remarks | 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053 |
Randy Joe Maddux | officer: Chief Operating Officer | 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121 |
Alexandra Kropotova | director | RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807 |
Gary Sender | director | C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020 |
Linda Washington Armstrong | director | 8800 HSC PARKWAY, BRYAN TX 77807 |
John Delta | officer: Principal Accounting Officer | 8800 HSC PARKWAY, BRYAN TX 77807 |
Eastern Capital Ltd | 10 percent owner | 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Robert L Erwin | officer: President | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
James P. Mullaney | officer: Chief Financial Officer | C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022 |
Carl Desantis | 10 percent owner | C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431 |
From GuruFocus
By PRNewswire PRNewswire • 08-10-2020
By PRNewswire PRNewswire • 06-04-2020
By PRNewswire PRNewswire • 07-28-2020
By PRNewswire PRNewswire • 12-02-2020
By PRNewswire PRNewswire • 05-07-2021
By PRNewswire PRNewswire • 08-05-2020
By PRNewswire PRNewswire • 01-13-2021
By PRNewswire PRNewswire • 08-21-2020
By PRNewswire PRNewswire • 07-08-2020
By GF Value GF Value • 04-09-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.